Poly Medicure Share News - Latest Updates, Live News & More

Latest news about Poly Medicure

Poly Medicure Expands Global Footprint with Strategic Acquisitions, Schedules Investor Call 3 days ago

Poly Medicure Limited is acquiring the Citieffe Group through its Netherlands-based entity, Poly Medicure B.V. The acquisition includes 100% ownership of Citieffe, a trauma and extremity fixation systems company, for an equity valuation of €18.80 million and a total enterprise value of €31.00 million. Citieffe reported €17.30 million in revenue and €3.10 million in EBITDA, with strong year-on-year growth. The acquisition provides Poly Medicure entry into the global orthopaedic market. Additionally, Poly Medicure has completed the acquisition of 90% economic rights in the PendraCare Group through its subsidiary, RisoR Holdings B.V.

Poly Medicure Completes PendraCare Group Acquisition, Secures 90% Economic Rights 4 days ago

Poly Medicure Acquires 90% Stake in PendraCare, Aims to Slash Cardiology Catheter Costs by 30% Sep 13, 2025

Poly Medicure Ltd. Executes Rs. 23.27 Crore Block Trade, Announces Investor Meet Sep 10, 2025

Poly Medicure Acquires 90% Stake in Netherlands-Based PendraCare Group for EUR 14.2 Million Sep 09, 2025

More news about Poly Medicure

05Sept 25

Poly Medicure Announces ₹3.50 Per Share Final Dividend for FY 2024-25

Poly Medicure Limited has declared a final dividend of ₹3.50 per equity share for FY 2024-25. The record date is set for September 18, 2025, with a book closure period from September 19 to September 25, 2025. The dividend is subject to shareholder approval at the AGM scheduled for September 25, 2025. The company has informed stock exchanges about the record date and book closure details in compliance with SEBI regulations.

05Sept 25

Poly Medicure Releases Audio Recording of PendraCare Group Acquisition Conference Call

Poly Medicure Limited has made public the audio recording of an analyst and investor conference call held on September 4, 2025, discussing the proposed acquisition of the PendraCare Group. The company's subsidiary, RisoR Holdings B.V., has entered into a Share Purchase Agreement to acquire 90% economic rights in Pendracare Holdings B.V. and Wellinq Medical B.V. This move aligns with regulatory requirements and demonstrates Poly Medicure's commitment to transparency in its strategic expansion within the medical devices sector.

03Sept 25

Poly Medicure Expands Global Footprint: Establishes Dutch Subsidiary for Strategic Acquisition

Poly Medicure Limited has incorporated RisoR Holdings B.V., a wholly owned step-down subsidiary in the Netherlands, with an issued capital of EUR 9.00. RisoR Holdings B.V. is set to acquire 90% economic rights in the PendraCare Group, comprising Pendracare Holdings B.V. and Welling Medical B.V. This strategic move aims to strengthen Poly Medicure's international presence and expand its product portfolio in the European medical devices market.

01Sept 25

Poly Medicure Set to Benefit from Potential GST Rate Cut on Medical Devices

The GST Council is proposing to reduce the tax rate on medical devices from 12% to 5%. This decision will be discussed in a meeting scheduled for September 3-4. If approved, it could significantly benefit companies like Poly Medicure by reducing tax burden, enhancing product affordability, improving competitiveness, and potentially fostering growth. The proposed change is expected to have a positive impact on the entire medical device industry in India, potentially leading to increased investments, innovation, and improved healthcare accessibility.

30Aug 25

Poly Medicure Anticipates Medical Device Demand Boost from Proposed GST Reforms

Poly Medicure's Managing Director, Himanshu Baid, discusses potential GST rate reduction for medical devices in India. The proposed change could lower consumables' GST from 12% to 5%, potentially reducing product prices by 6-7% and increasing demand for locally manufactured devices. The Indian MedTech market, valued at $15 billion with $8 billion in imports, is growing at 12-15% annually. Poly Medicure is diversifying its export markets beyond the US, focusing on Europe, Asia, and Latin America, with new product lines for the US market expected by FY27.

20Aug 25

Poly Medicure Secures NCLT Approval for ₹33.15 Crore Acquisition of Himalayan Mineral Waters

Poly Medicure Limited has received NCLT approval for its ₹33.15 crore resolution plan to acquire Himalayan Mineral Waters Private Limited. The acquisition includes a manufacturing facility in Haridwar and land in Bharuch, Gujarat. This move is expected to expand Poly Medicure's manufacturing capabilities and create operational synergies in areas such as operations, procurement, marketing, and sales. The acquisition is set to be completed within 30 days from the effective date.

14Aug 25

Poly Medicure Reports No Deviations in QIP Fund Utilization, Rs 12,772.45 Lakh Deployed

Poly Medicure Limited has utilized Rs 12,772.45 lakh out of Rs 98,534.37 lakh raised through QIP as of June 30, 2025. The funds are being used for capital expenditure, inorganic initiatives, and general corporate purposes. Unutilized funds of Rs 85,761.92 lakh are invested in mutual funds, fixed deposits, and a monitoring account. The company's Audit Committee confirmed adherence to stated objectives, with CRISIL Ratings Limited overseeing the process.

11Aug 25

Poly Medicure Slashes Export Growth Guidance to 5-10%

Poly Medicure, a prominent medical devices manufacturer, has significantly reduced its export growth guidance from 15-18% to 5-10%. This revision suggests potential challenges in the global market and could impact the company's revenue and financial performance. The adjustment may necessitate strategic shifts in export strategies and could influence investor sentiment.

08Aug 25

Poly Medicure Reports Revenue Growth to 4B Rupees in Q1 Results

Poly Medicure Limited reported Q1 revenue of 4.00 billion rupees, a 3.90% year-on-year increase. EBITDA rose slightly to 1.06 billion rupees, but the EBITDA margin declined to 26.32%. The renal care business grew by 46.20% year-on-year, selling about 130 dialysis machines. The company initiated a clinical registry for its RisoR Everolimus Eluting Stent System, signed contract manufacturing agreements in the US and Hong Kong, established a subsidiary in Brazil, and continued investing in capacity expansion with a Q1 capital expenditure of 95.00 crore rupees.

20Jun 25

Poly Medicure Faces Potential Impact as EU Bars Chinese Firms from Medical Device Tenders

The European Commission has announced a new policy excluding Chinese companies from public tenders for medical devices valued over 5 million euros in the EU. This decision could potentially benefit non-Chinese manufacturers like India's Poly Medicure. The policy change may alter the competitive landscape in the European medical device market, possibly creating new opportunities for Poly Medicure to expand its presence. However, the company may need to reassess its European market strategy in response to this development.

07May 25

Poly Medicure Reports Robust Q4 Results with 34% Profit Surge

Poly Medicure Ltd. reported a consolidated net profit of 918.30 million rupees in Q4, up 34.3% year-over-year. Revenue increased by 18.9% to 4.40 billion rupees. The company's board recommended a dividend of 3.50 rupees per equity share. Quarter-on-quarter, net profit rose by 7.7% from 852.30 million rupees in the previous quarter.

06May 25

Poly Medicure Reports Robust Q4 FY23 Results, Announces Dividend

Poly Medicure Ltd, a leading medical devices manufacturer, has announced impressive Q4 FY23 results. Revenue increased by 18.90% to ₹4,400.00 crore, EBITDA grew by 23.40% to ₹1,190.00 crore, and net profit surged by 34.30% to ₹918.30 crore compared to Q4 FY22. The EBITDA margin improved by 100 basis points to 27.10%. The company also declared a dividend of ₹3.50 per equity share.

16Apr 25

Hindustan Syringes & Medical Devices Ltd. May Benefit from US Tariffs on Chinese Medical Supplies

The United States has implemented a 245% tariff increase on syringes and needles from China, potentially reshaping the global medical supply chain. This move could benefit non-Chinese manufacturers, particularly India's Hindustan Syringes & Medical Devices Ltd. (HMD). The tariff may create new export opportunities for HMD in the U.S. market, but capitalizing on this will require increased production capacity, compliance with U.S. standards, and strengthened distribution networks. The industry-wide impact includes potential supply chain diversification and increased competition among non-Chinese manufacturers.

11Mar 25

Poly Medicure Secures MDR Certification for 54 Products, Boosting European Market Prospects

Poly Medicure Limited has obtained Medical Device Regulation (MDR) certification for 54 of its products, enhancing its access to the European Union market. The certification covers products in various medical specialties including Infusion Therapy, Vascular Access, Renal Care, and others. This achievement is expected to strengthen Poly Medicure's position in the European market, which currently accounts for about half of the company's export revenue. The certification demonstrates the company's compliance with stringent EU safety and quality standards for medical devices.